Skip to content

Dermalux

Active Private limited companyfounded 2023active for 3 yearsPlace de l'Eglise 27-29, 4720 La CalamineKBO/BCE: BE 0797.625.852

Lifetime

3 annual accounts with figures on one time axis
peak of €127,589 in 2025
€127,589▲ 1.2%
peak of €100,510 in 2025
€100,510▲ 1.3%
peak of €54,237 in 2024
€5,000▼ 90.8%
€186,033▲ 53.1%
Board1 name since 2023
1 director
Documentsfilings and deeds
06-07-202625 days before the deadline
2025micro format
Dividend €149,747Equity from €54,237 to €5,000Debts from €121,524 to €186,033

Key points

from the 2025 annual accounts

Equity

€5,000 ▼ 90.8%
54,2372024+100,510Profit-149,747Dividend5,0002025

Dermalux paid out €149,747 in dividends. That is 149% of the 2025 profit.

Turnover

≈ €240,000 estimated

The accounts state no turnover.

Debts

€186,033 97% of the balance sheet
Suppliers 18%Taxes and wages 35%Other 47%

Investments

€5,997 46.5 times depreciation

Green is investment, beige is depreciation.

Liquidity

1.00 was 1.45 in 2024

Short-term debts rose from €121,524 to €186,033.

Position in the sector

2.6%

Lower solvency than 92% of companies in human health. Sector median 63.0% · 21,336 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 2,156 companies had the same profile as Dermalux has now. Each dot stands for 6 companies, two years later.

94.1%
were still trading
2.8%
stopped another way
3.0%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency under 10%
  • a profit of 5% of the balance sheet or more

Another 0.2% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 2,156 companies, not a prediction for Dermalux. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • 100 sharesdeed of 27-01-2023
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0797625852
Registered office moved from Eupen to La Calamine The registered office moved from Loten 3 in 4700 Eupen to Kirchplatz 27-29 in 4720 Kelmis · Board meeting of 01-12-2023 · Gazette deed
First establishment At the time the registered office was still in Eupen, Loten 3 in.
Incorporation Founding capital of €5,000, 100 shares · Founded by · appointed as director · published on 27-01-2023 · Gazette deed
All 8 events

Comparable companies

same main activity, similar in size and age
Company
Dermalux La Calamine €191,033 €127,589 2.6% -
PHLEBEX Beauraing €188,365 €130,652 66.0% -
Dr. Caroline Van Damme - Psychiatrie Chaumont-Gistoux €185,771 €121,039 35.9% -
RAYEN PEDO PSY Anderlecht €208,552 €127,078 76.4% -
DBM EMERGENCY Chapelle-lez-Herlaimont €204,993 €130,586 80.3% -
LPLASTIC Jurbise €203,654 €135,361 67.8% -
Leticia Barrios Cardiologie Bierbeek €207,335 €128,408 92.3% -

These companies have the same main activity as Dermalux: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €186,000 and €209,000, founded between 2022 and 2023.

Official details

Source: KBO
Status
Active since 25-01-2023Normal situation
Activity
Specialist medical practiceNACE 86220
Establishment unit
2.340.842.5034720 La Calamine, registered on 31-01-2023
Financial year end
31 December
Peppol
Reachable since 10-12-2025
Company details

Annual accounts 2025

€191,033▲ 8.7%
Filing
Filed on 06-07-2026, 25 days before the end of the filing period
Financials

Insights on Dermalux

Dermalux files the micro format. That format states no turnover. The gross margin rose from €93,126 in 2023 to €127,589 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about Dermalux

What is the company number of Dermalux?
The company number of Dermalux is 0797.625.852. The VAT number is the same number with BE in front: BE 0797.625.852.
Where is Dermalux based?
The registered office is at Place de l'Eglise 27-29, 4720 La Calamine.Company details
What does Dermalux do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of Dermalux?
Dermalux is a private limited company (BV).
When was Dermalux founded?
Dermalux was founded on 25-01-2023.
Is Dermalux still active?
Yes, Dermalux is an active enterprise in the KBO register.
What is the turnover of Dermalux?
The turnover in financial year 2025 is ≈ €240,000. This figure is estimated from the gross margin of €127,589 and 40 comparable companies (NACE 86220). It probably lies between €200,000 and €320,000.Financials
Is Dermalux profitable?
In financial year 2025, Dermalux made a profit of €100,510.
Where can I find the annual accounts of Dermalux?
Dermalux filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of Dermalux due?
Dermalux must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.